Checkpoint Inhibitor Combinations Therapy as First Line for Inoperable Lung Cancer Via IT

NCT06483347 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

90

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer
Inoperable Disease

Interventions

DRUG: ipilimumab+pembrolizumab or ipilimumab+durvalumab, idarubicin, bevacizumab

Sponsor

Second Affiliated Hospital of Guangzhou Medical University